NASDAQ:NEXI NexImmune (NEXI) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 08/5/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About NexImmune Stock (NASDAQ:NEXI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NexImmune alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range$0.00▼$0.1052-Week Range$0.00▼$1.34VolumeN/AAverage Volume6,303 shsMarket Capitalization$279.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Read More NexImmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreNEXI MarketRank™: NexImmune scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NexImmune. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NexImmune is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NexImmune is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNexImmune has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.27% of the outstanding shares of NexImmune have been sold short.Short Interest Ratio / Days to CoverNexImmune has a short interest ratio ("days to cover") of 37, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNexImmune does not currently pay a dividend.Dividend GrowthNexImmune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.27% of the outstanding shares of NexImmune have been sold short.Short Interest Ratio / Days to CoverNexImmune has a short interest ratio ("days to cover") of 37, which indicates bearish sentiment.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for NexImmune this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NexImmune insiders have not sold or bought any company stock.Percentage Held by Insiders14.90% of the stock of NexImmune is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.85% of the stock of NexImmune is held by institutions.Read more about NexImmune's insider trading history. Receive NEXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter. Email Address NEXI Stock News HeadlinesNeoleukin Therapeutics (NASDAQ:NLTX) and NexImmune (NASDAQ:NEXI) Head-To-Head ComparisonAugust 4 at 2:15 AM | americanbankingnews.comShattuck Labs stock craters following pipeline and job cutsOctober 2, 2024 | msn.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)NexImmune moves forward with wind-down processAugust 31, 2024 | bizjournals.comNexImmune adjourns special meeting to explore optionsAugust 4, 2024 | investing.comNEXI Stock Alert: NexImmune Delists From NasdaqJuly 12, 2024 | investorplace.comWhat Is Going on With NexImmune (NEXI) Stock Today?July 11, 2024 | investorplace.comNexImmune, Inc. Common Stock (NEXI) After-HoursMay 26, 2024 | nasdaq.comSee More Headlines NEXI Stock Analysis - Frequently Asked Questions How have NEXI shares performed this year? NexImmune's stock was trading at $0.1151 at the beginning of 2025. Since then, NEXI shares have decreased by 99.8% and is now trading at $0.0002. How were NexImmune's earnings last quarter? NexImmune, Inc. (NASDAQ:NEXI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($16.25) earnings per share for the quarter, topping the consensus estimate of ($16.75) by $0.50. When did NexImmune's stock split? NexImmune's stock reverse split on Thursday, October 19th 2023.The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did NexImmune IPO? NexImmune (NEXI) raised $75 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 4,700,000 shares at $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO. How do I buy shares of NexImmune? Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NexImmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that NexImmune investors own include Athenex (ATNX), Achilles Therapeutics (ACHL), TherapeuticsMD (TXMD), Bolt Biotherapeutics (BOLT), KLX Energy Services (KLXE), Lannett (LCI) and Exela Technologies (XELA). Company Calendar Last Earnings11/12/2021Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NEXI CIK1538210 Webwww.neximmune.com Phone301-825-9810FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($18.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.34 million Net MarginsN/A Pretax MarginN/A Return on Equity-534.32% Return on Assets-213.72% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book0.00Miscellaneous Outstanding Shares1,395,000Free Float1,187,000Market Cap$279.00 OptionableNot Optionable Beta1.94 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:NEXI) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.